Acción ALVO ALVOTECH
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Alvotech Nyse

Acciones

ALVO

LU2458332611

Mercado cerrado - Nyse
Otros sitios de cotización
 22:00:00 02/05/2024 		Varia. Cinco días. Varia. 1 de enero.
14,51 USD +0,21 % Gráfico intradía de Alvotech +6,94 % +54,69 %
30/04 Alvotech fabricará el biosimilar de Humira para Quallent Pharmaceuticals MT
30/04 Alvotech fabricará el biosimilar de Humira Adalimumab-ryvk para Quallent MT

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Alvotech Announces Positive Topline Results From Confirmatory Clinical Study For Its Proposed Golimumab Biosimilar
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
Alvotech - U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-FreeInterchangeable Biosimilar to Humira
Alvotech And Teva's Selarsdi™ (ustekinumab-aekn), Biosimilar To Stelara® Approved By FDA
Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
FDA Approval Of Alvotech/Teva Ustekinumab Biosimilar
Cigna to offer Humira rivals with $0 copay at specialty pharmacy
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi
Alvotech’s Simponi Biosimilar Candidate Shows Efficacy in Confirmatory Study
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
Alvotech Announces Topline Results from A Confirmatory Clinical Study for AVT05, A Proposed Biosimilar for Simponi
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira
Sector Update: Health Care Stocks Advance Late Afternoon
Sector Update: Health Care Stocks Rise Friday Afternoon
Sector Update: Health Care
Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción ALVO
  4. Acción ALVO
  5. Noticias Alvotech
  6. Otros idiomas